Answers are grounded in this paper and cite their sources.
We conclude that SB290157 is safe and effective with and without late IVT following TE stroke. Therefore, C3a receptor antagonist therapy represents a promising candidate for clinical translation in stroke, particularly as an adjuvant to IVT.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: